T cell therapy companies develop treatments that use a patient’s own or donor-derived immune cells to recognise and attack disease. These approaches are primarily used in cancer immunotherapy, with emerging applications across autoimmune and infectious diseases.
This category includes companies working on:
Browse 48 UK T cell therapy companies below.
Longer-lasting RNA medicines and immune-stealthed CAR-T research
Cambridge RNA Technologies develops experimental RNA platforms intended to extend the duration of therapeutic gene expression. Its research includes technologies for longer-lasting RNA medicines. In collaboration with Anglia Ruskin University, the company has investigated immune-stealth approaches for donor-derived…
CRISPR-engineered tumour-infiltrating lymphocyte therapy
Intima Bioscience is a clinical-stage biotechnology company developing CRISPR gene-edited tumour-infiltrating lymphocyte therapies for solid tumours. Its platform targets CISH, an intracellular immune checkpoint that suppresses T cell activity against tumours; CRISPR knockout of CISH in patient-derived TILs enhances…
ML platform designing optimised CAR-T and BiTE therapies
Coding Bio is a biotechnology company using machine learning and high-throughput screening to design chimeric antigen receptor and bispecific T cell engager therapies. The company's platform screens millions of modular protein candidates in living cells to identify designs that best induce immune responses, generating…
TCR-based bispecific therapeutics for cancer and autoimmune disease
T-Therapeutics is a biotechnology company developing T cell receptor-based therapeutics for cancer and autoimmune disease. Using a humanised TCR mouse platform to generate high-affinity, antigen-specific human T cell receptors, the company engineers bispecific molecules that redirect a patient's own T cells to…
Personalised T cell therapy platform for solid tumour treatment
Swarm Oncology is a pre-clinical biotechnology company developing personalised T cell therapies for advanced solid cancers. Its platform combines in vivo immune priming with proprietary ex vivo cell processing to generate large numbers of potent, non-exhausted T cells with tumour-homing phenotypes, addressing a key…
TCR therapeutic discovery platform targeting solid tumours
T-Cypher Bio is a pre-clinical biotechnology company developing T-cell receptor therapeutics using its proprietary platform, which integrates immunopeptidomics, bead-display microfluidics, and immune synapse mapping to identify novel intracellular targets and potent TCRs directly from patient tissue. The approach…
Generative AI platform for T cell receptor and antibody therapeutics
Etcembly is a biotech company using generative AI to discover and engineer T cell receptor and antibody therapeutics. The company's platform applies large language models to TCR sequence data to design candidates with high affinity and selectivity for cancer and autoimmune disease targets. Its lead programme, ETC-101,…
GMP lentiviral and retroviral vector design and manufacture for CGT
ViroCell Biologics is a specialist contract development and manufacturing organisation providing GMP design and manufacture of lentiviral and retroviral vectors for cell and gene therapy clinical trials. The company serves academic and corporate innovators developing CAR-T therapies, rare disease gene therapies, and…